PMID- 28604111
OWN - NLM
STAT- MEDLINE
DCOM- 20180322
LR  - 20181202
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 33
IP  - 10
DP  - 2017 Oct
TI  - Basal insulin initiation use and experience among people with type 2 diabetes 
      mellitus with different patterns of persistence: results from a multi-national 
      survey.
PG  - 1833-1842
LID - 10.1080/03007995.2017.1341403 [doi]
AB  - BACKGROUND AND OBJECTIVE: People with type 2 diabetes mellitus (T2DM) often 
      interrupt basal insulin treatment soon after initiation. This study aimed to 
      describe the experiences during and after basal insulin initiation among people 
      with T2DM with different persistence patterns. METHODS: Adults with T2DM from 
      France, Germany, Spain, UK, US, Brazil, and Japan were identified from consumer 
      panels for an online survey. Respondents who initiated basal insulin 3-24 months 
      prior to survey date were categorized as continuers (no gaps of >/=7 days in 
      insulin treatment); interrupters (first gap >/=7 days within 6 months of initiation 
      and restarted insulin); and discontinuers (stopped insulin for >/=7 days within 6 
      months of initiation without restarting). RESULTS: Among 942 participants, 
      continuers were older than interrupters and discontinuers (46, 37, and 38 years, 
      respectively, p < .01). Continuers reported having fewer concerns before and 
      after insulin initiation than interrupters and discontinuers, while interrupters 
      had the most concerns. Continuers also reported fewer challenges during the first 
      week of insulin use. Continuers were more likely to respond that insulin use had 
      a positive impact on specific aspects of life than interrupters and 
      discontinuers, for example on glycemic control (73.0%, 63.0%, and 61.8%, 
      respectively; p < .01 vs. continuers). CONCLUSION: Among people with T2DM with 
      different persistence patterns after basal insulin initiation there were 
      significant differences in patient characteristics and experience during and 
      after insulin initiation. Interrupters and discontinuers more frequently reported 
      having concerns and challenges during the initiation process, negative impacts 
      after initiation, and less improvement in glycemic control than continuers.
FAU - Perez-Nieves, Magaly
AU  - Perez-Nieves M
AD  - a Eli Lilly and Company , Indianapolis , IN , USA.
FAU - Ivanova, Jasmina I
AU  - Ivanova JI
AD  - b Analysis Group Inc. , New York , NY , USA.
FAU - Hadjiyianni, Irene
AU  - Hadjiyianni I
AD  - c Lilly Deutschland GmbH , Bad Homburg , Germany.
FAU - Zhao, Chen
AU  - Zhao C
AD  - b Analysis Group Inc. , New York , NY , USA.
FAU - Cao, Dachuang
AU  - Cao D
AD  - a Eli Lilly and Company , Indianapolis , IN , USA.
FAU - Schmerold, Luke
AU  - Schmerold L
AD  - b Analysis Group Inc. , New York , NY , USA.
FAU - Kalirai, Samaneh
AU  - Kalirai S
AD  - a Eli Lilly and Company , Indianapolis , IN , USA.
FAU - King, Sarah
AU  - King S
AD  - d Analysis Group Inc. , Boston , MA , USA.
FAU - DeLozier, Amy M
AU  - DeLozier AM
AD  - a Eli Lilly and Company , Indianapolis , IN , USA.
FAU - Birnbaum, Howard G
AU  - Birnbaum HG
AD  - d Analysis Group Inc. , Boston , MA , USA.
FAU - Peyrot, Mark
AU  - Peyrot M
AD  - e Loyola University Maryland , Baltimore , MD , USA.
LA  - eng
PT  - Journal Article
DEP - 20170707
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
SB  - IM
MH  - Adult
MH  - Cross-Sectional Studies
MH  - *Diabetes Mellitus, Type 2/drug therapy/epidemiology
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin/*therapeutic use
MH  - Medication Adherence/*statistics & numerical data
MH  - Middle Aged
OTO - NOTNLM
OT  - Type 2 diabetes
OT  - basal insulin
OT  - initiation
OT  - long-acting insulin
EDAT- 2017/06/13 06:00
MHDA- 2018/03/23 06:00
CRDT- 2017/06/13 06:00
PHST- 2017/06/13 06:00 [pubmed]
PHST- 2018/03/23 06:00 [medline]
PHST- 2017/06/13 06:00 [entrez]
AID - 10.1080/03007995.2017.1341403 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2017 Oct;33(10):1833-1842. doi: 10.1080/03007995.2017.1341403. 
      Epub 2017 Jul 7.